---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196467"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:05:58.390388+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q2: $203.2M cash, 9 patients enrolled, Grade 4 ICANS DLT resolved

## Summary
- R&D expenses $23.4M (Q2 2023: $11.8M); G&A $6.9M (Q2 2023: $4.1M).
- Cash, equivalents and ST investments $203.2M, expected to fund ops into H1 2026.
- Nine patients enrolled across RESET program as of Aug 5; 22 U.S. sites now active.
- LN patient with active refractory disease had Grade 4 ICANS DLT; IDMC recommended study proceed at current dose.
- New Lonza CDMO agreement and expanded Cellares partnership for CABA-201 manufacturing.

## SEC filing metadata
- accession: 0001193125-24-196467
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312524196467/0001193125-24-196467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312524196467/d884570d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196467
- JSON: https://secwatch.observer/filing/0001193125-24-196467.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196467.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.